In the BioHarmony Drug Report Database
Entereg (alvimopan) is a small molecule pharmaceutical. Alvimopan was first approved as Entereg on 2008-05-20. It is known to target kappa-type opioid receptor, mu-type opioid receptor, and delta-type opioid receptor. Entereg’s patent is valid until 2030-02-12 (FDA).
Image (chem structure or protein)